Showing 1791-1800 of 2314 results for "".
- Cigna Rolls Out New Plan to Fully Cover Multi-Million Dollar Gene Therapieshttps://modernod.com/news/cigna-rolls-out-new-plan-to-fully-cover-multi-million-dollar-gene-therapies/2479539/Health insurer Cigna Corp has introduced a plan to fully cover costs for expensive gene therapies, eliminating any out-of-pocket payments for customers, according to a Reuters report. Gene therapies, which in general aim to treat di
- Hoya Vision Care Plans $25 Million Dollar Expansion of U.S. Labhttps://modernod.com/news/hoya-vision-care-plans-25-million-dollar-expansion-of-u-s-lab/2476833/Hoya Vision Care announced plans to invest more than $25 million in its Ramsey, Minnesota facility, according to a report in VisionMonday. The investment in facility
- ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP)https://modernod.com/news/proqr-announces-clearance-of-ind-to-start-clinical-trial-of-qr-1123-in-patients-with-autosomal-dominant-retinitis-pigmentosa-adrp/2476802/ProQR Therapeutics announced that the FDA has cleared the investigational new drug (IND) application for QR-1123. ProQR plans to start enrolling patients in a phase 1/2 trial for QR-1123 in 2019. QR-1123 is a first-in-class investigational oligonucleotide designed to address the underlying
- FDA Does Not Approve Kala Pharmaceuticals’ NDA for Dry Eye Disease Candidatehttps://modernod.com/news/fda-does-not-approve-kala-pharmaceuticals-nda-for-dry-eye-disease-candidate/2476799/Kala Pharmaceuticals announced that it received a complete response letter (CRL) from the FDA regarding the company’s new drug application (NDA) for KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease. The FDA indicated that efficacy data from an additional clinica
- Doctor Alexa Will See You Now: Is Amazon Primed To Come To Your Rescue?https://modernod.com/news/doctor-alexa-will-see-you-now-is-amazon-primed-to-come-to-your-rescue/2476782/Now that it’s upending the way you play music, cook, shop, hear the news and check the weather, the friendly voice emanating from your Amazon Alexa-enabled smart speaker is poised to wriggle its way into all things health care. Amazon has big ambitions for its devices, according to a
- Double-Barreled Biologic for Diabetic Retinopathy Emerginghttps://modernod.com/news/double-barreled-biologic-for-diabetic-retinopathy-emerging-2/2476749/Investigators searching for new ways to manage diabetic macular edema are targeting pathways beyond vascular endothelial growth factor (VEGF), the only pathway for which there are approved therapies, and are developing treatments that can be administered less often, according to a Medscape
- FDA Does Not Approve Bausch Health, Eton’s Pharma’s EM-100 for Allergic Conjunctivitishttps://modernod.com/news/fda-does-not-approve-bausch-health-etons-pharmas-em-100-for-allergic-conjunctivitis/2476731/Eton Pharmaceuticals on Friday said that partner Bausch Health Companies has received a complete response letter from the FDA for its filing seeking approval of the investigational therapy EM-100 to treat ocular itching associated with allergic conjunctivitis. “We
- Double-Barreled Biologic for Diabetic Retinopathy Emerginghttps://modernod.com/news/double-barreled-biologic-for-diabetic-retinopathy-emerging/2476720/Investigators searching for new ways to manage diabetic macular edema are targeting pathways beyond vascular endothelial growth factor (VEGF), the only pathway for which there are approved therapies, and are developing treatments that can be administered less often, according to a
- Aerpio Pharmaceuticals Does Not Meet Primary Endpoint in Phase 2b Study for Diabetic Retinopathyhttps://modernod.com/news/aerpio-pharmaceuticals-does-not-meet-primary-endpoint-in-phase-2b-study-for-diabetic-retinopathy/2476386/Aerpio Pharmaceuticals announced topline results from the company’s TIME-2b study, a phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate, AKB-9778, for patients with moderate to severe non-proliferative diabetic retinopathy (NPDR). Administration o
- Apellis Resumes Dosing in Its Phase 3 Program for Patients with Geographic Atrophyhttps://modernod.com/news/apellis-resumes-dosing-in-its-phase-3-program-for-patients-with-geographic-atrophy/2479589/Apellis Pharmaceuticals announced that it has resumed enrollment in its two phase 3 GA trials (DERBY & OAKS) with intravitreal APL-2 for the treatment of geographic atrophy (GA). In October 2018, Apellis